• Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase III study published in The Lancet showed patients with active psoriatic arthritis who received either Stelara (ustekinumab) 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint, compared to patients receiving placebo.